Oocyte Donation: Corifollitropin alfa vs. Daily rFSH

We are studying whether Corifollitropin alfa can help increase the number of eggs collected from oocyte donors compared to standard daily treatments. This trial involves women using hormone suppression to improve egg quality.

1-2 years 6-10 visits Confirmation phase (III)No Placebo Partially Remote Standard Medicines InjectionGynecology and Obstetrics

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Corifollitropin Alfa

Corifollitropin alfa is a long-acting fertility hormone used to stimulate ovarian follicle growth during assisted reproductive treatments.

Follitropin Beta

Follitropin beta is a hormone substance used to stimulate the ovaries to produce eggs during fertility treatments.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Ivi Valencia S.L.

Medicina Reproductiva

Mislata, Spain

Sponsor: Ivi Valencia S.L.

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.